文献速递流行病学与生物统计真实世界研究与卫生经济

多重有效性结局下的成本效果分析:一种概率方法

Cost-effectiveness analysis under multiple effectiveness outcomes: A probabilistic approach.
PubMed 文献 · Stat Med · 2023-07-03

针对新治疗与标准治疗在多个有效性指标下的成本效果评价,提出两种基于概率的指标:一为新治疗在多项有效性指标上更有效且成本更低的条件下概率,二为新治疗成本更低且健康获益更大的条件下概率;采用百分位 bootstrap 与 U 统计量构建置信限,数值结果显示覆盖概率准确,并以 2 型糖尿病治疗研究示例。

要点

  • 提出两种概率指标用于多重有效性结局下的成本效果评价。
  • 指标可纳入成本和有效性的阈值,为决策者提供灵活性。
  • 百分位 bootstrap 与 U 统计量法置信限覆盖概率准确。

核心结论

  • 提出的概率指标可用于多重有效性结局下新治疗与标准治疗的成本效果评价,且置信限能准确维持覆盖概率。

研究设计与样本

  • 方法学研究,提出概率指标并开发参数百分位 bootstrap 与非参数 U 统计量估计程序,以 2 型糖尿病治疗研究进行示例。

主要发现

  • 数值结果表明所提出的置信限能准确维持覆盖概率。

关键数值与推荐

  • 指标一:新治疗在多项有效性指标上更有效且成本更低的条件下概率。
  • 指标二:新治疗成本更低且健康获益更大的条件下概率。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Probability based criteria are proposed for the assessment of cost-effectiveness of a new treatment compared to a standard treatment when there are multiple effectiveness measures. Depending on the preferences of a policy maker, there are several options to define such criteria. Two such metrics are investigated in detail. One metric is defined as the conditional probability that a new treatment is more effective with respect to the multiple effectiveness measures for patients having lower costs under the new treatment. A second metric is defined as the conditional probability that a new treatment is less costly for patients having greater health benefits under the new treatment. The metrics offer considerable flexibility to a policy maker as thresholds for cost and effectiveness can be incorporated into the metrics. Parametric confidence limits are developed using a percentile bootstrap approach assuming multivariate normality for the joint distribution of the log(cost) and effectiveness measures. A non-parametric estimation procedure is also developed using the theory of U-statistics. Numerical results indicate that the proposed confidence limits accurately maintain coverage probabilities. The methodologies are illustrated using a study on the treatment of type two diabetes. Code implementing the proposed methods are provided in the supporting information.

来源:Stat Med,查看原文。版权归原作者所有。

引用

  1. Arsham A, Bebu I, Mathew T, et al. Cost-effectiveness analysis under multiple effectiveness outcomes: A probabilistic approach. Stat Med. 2023. PMID: 37401188. doi:10.1002/sim.9841

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。